Novonesis (Novozymes) B (0Q4U)
LSE
Real-time Data
07:00 AM
Day's Range
442.7552 wk Range
337.50Overview - 0Q4U - Novonesis (Novozymes) B
Key Statistics
Valuation
Enterprise Value
85.19B
P/E (Trailing)
‪36.16‬
P/E (Forward)
‪34.75‬
PEG Ratio
‪-1.91‬
Price / Sales (TTM)
‪6.95‬
Price / Book
‪9.22‬
EV / EBITDA
‪15.12‬
Profitability
Gross Margin
‪56.70%‬
Profit Margin
‪19.31%‬
Operating Margin
‪25.03%‬
Return on Assets
‪10.14%‬
Return on Equity
‪26.20%‬
Ownership
Shares Outstanding
466.22M
Float
194.75M
Held by Insiders
‪8.00%‬
Held by Institutions
‪40.45%‬
Price stats
Beta
‪0.44‬
50-Day Avg
‪414.46‬
200-Day Avg
‪393.89‬
Dividends
Payout Ratio
‪48.70%‬
Frequency
Annual
Market Cap - 0Q4U - Novonesis (Novozymes) B
Peers - 0Q4U - Novonesis (Novozymes) B
Peer Comparison
Compared with companies in Specialty Chemicals listed on LSE.
Profile Summary - 0Q4U - Novonesis (Novozymes) B
About
Novonesis (Novozymes) B is the Class B share of Novonesis A/S, a leading biotechnology company headquartered in Lyngby, Denmark. Formed in 2024 through the merger of Novozymes and Chr. Hansen, it holds a dominant near-50% market share in industrial enzymes and microbial solutions worldwide. The company develops and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
